Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis (Savara SAV008-02) , protocol number NCT03597347 SAVARA SAV008-02

    This study will look at the effectiveness of the inhaled drug molgramostim, a drug intended to treat infections in the lung. This study is open-label with no control. This means that all participants will receive the study drug. In this study, researchers will test the effectiveness of inhaled molgramostim by monitoring NTM cultures. They will also monitor lung function, BMI and quality of life. This study may require sputum samples, lung function tests and/or other measures.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      19

    • Length of Participation:

      72 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA & Australia

    Phase 3 study of inacaftor in babies who have a CFTR gating mutation , protocol number NCT02725567 VX15-770-124

    This two-part, open label study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.

    • Age:

      0 Months to 24 Months

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites & Australia

    Phase 2 study of VX-440 combination drug in people with cystic fibrosis. , protocol number NCT02951182 VX15-440-101

    This study is taking place at multiple care centres accross the US. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661)

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      11

    • Length of Participation:

      57

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    GI symptoms observational study (GALAXY) , protocol number NCT03801993 GALAXY-OB-18

    This study will collect information on gastrointestinal (GI) symptoms that people with CF experience.

    • Age:

      2 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      29 days

    Contact us about this clinical Trial >
  • OtherEnrolling Location: USA

    Study of SPI-1005 in people with CF ages 18 and older (Sound Pharma SPI-3005-501.2) , protocol number NCT02819856 SPI-3005-501.2

    This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      6

    • Length of Participation:

      49 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 3 study of lumacaftor/ivacaftor (OrkambiĀ®) in babies with two copies of the F508del CFTR mutation , protocol number NCT03601637 VX16-809-122

    This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (OrkambiĀ®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.

    • Age:

      1-2 years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      11

    • Length of Participation:

      38

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Sweat chloride observational study (CHEC-OB-17) , protocol number NCT03350828 CHEC-OB-17

    This study is taking place at multiple care centers across the U.S. It will look at sweat chloride concentration in people who are currently taking CFTR modulators. Researchers will test the effectiveness of CFTR modulators by measuring change in sweat chloride concentration. Sweat chloride measures that are collected in the study visit will be analyzed in combination with data from the CF Foundation Patient Registry. This study is for people with cystic fibrosis who are enrolled in the CF Foundation Patient Registry and have been taking a CFTR modulator for at least three months before enrolling. This study will consist of a single study visit and will require a sweat test.

    • Age:

      4 months and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      1 Day

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation (VX17-659-103) , protocol number NCT03460990 VX17-659-103

    This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. It will look at the effectiveness and safety of the drug VX-659 in combination with ivacaftor and tezacaftor. It is for people with CF ages 12 and older who have two copies of the F508del CFTR mutation.

    • Age:

      12 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      7

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Multiple care centres across the US

    OPTION: Study of AzurRx MS1819 in people with cystic fibrosis and exocrine pancreatic insufficiency who are 18 years and older , protocol number NCT03746483 AzurRX AZ-CF2001

    This trial will look at the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy. Sponsor: AzurRx BioPharma, Inc

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      10

    • Length of Participation:

      11 weeks

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: Europe/UK

    A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibro , protocol number A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibro NCT03698448

    Randomized, double blind, placebo controlled study. The study has two parts: Dose-finding part, followed by longer term follow-up (6 months)

    • Age:

      12 years and older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 81-90 (of 178)
     |<  <  5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14  >  >|